Pharma BD Deal Intelligence
BioSpace detailed the $77/share offer (1.6331 New Endo shares + $1.16 cash), the $233M cash collar protection, and the spin-off of Knight Therapeutics carrying…
GEN catalogued Paladin's >60-product Canadian portfolio and framed the transaction as accelerating Endo's transformation into a 'top-tier global specialty…
The deal will allow Endo to reincorporate in Ireland with a lower tax rate, giving it an edge as it pursues more pharmaceutical takeovers; Piper Jaffray…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Endo to acquire Paladin Labs in stock-and-cash transaction valued ~$1.6B; folded both into new Irish holding company (tax inversion). $75M expected annual cost synergies.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Health Solutions Inc. / Paladin Labs Inc. (this deal) | 2013 | $1.6B | 28 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2014 | $225M | 21 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2013 | $225M | 19 |
| Endo Health Solutions Inc. / NuPathe Inc. | 2013 | $271M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Endo Health Solutions Inc. deals · Other deals